Data Sheet 1_Efficacy and safety of local consolidative therapy combined with systemic the

Heqiao Han's systematic review and meta-analysis, published on figshare in April 2026, evaluates the impact of local consolidative therapy combined with systemic therapy for driver-negative oligometastatic non-small cell lung cancer. The analysis pools data from 13 studies encompassing 1,698 patients. It reports hazard ratios for overall and progression-free survival, response rates, and adverse events.

Use Cases

• Validate the survival benefit of local consolidative therapy based on pooled hazard ratios for overall and progression-free survival.
• Assess treatment safety profiles based on the reported risk ratios for adverse events.
• Inform clinical trial design based on subgroup analyses incorporating immunotherapy-based regimens.
• Support evidence-based treatment guidelines based on the results of sensitivity analyses and publication bias assessment.

Strengths

• Analysis is based on a systematic review of 13 studies with 1,698 patients.
• Reports specific pooled effect sizes, including hazard ratios with 95% confidence intervals for survival outcomes.
• Includes subgroup and sensitivity analyses to test the robustness of findings.
• Registered with PROSPERO (CRD420261351878), indicating a predefined protocol.

Limitations

• The dataset is a 352 KB DOCX document; the underlying tabular meta-analysis data is not directly accessible.
• Column-level documentation for any statistical tables is absent; data semantics must be inferred from the text.
• Row count for any underlying data tables is unknown, which may limit suitability assessment for computational reuse.

Provenance

Source

figshare, author Heqiao Han.

Collection Method

Systematic review and meta-analysis of literature from PubMed, Embase, and Cochrane Library through December 2025.

Time Range

Literature search through December 2025.

Freshness

Last updated 2026-04-20 04:11:43.

Geography

null